Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.05 USD | -2.88% | -4.25% | -26.36% |
05-15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
04-30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.36% | 37.17M | |
+33.20% | 49.46B | |
+1.97% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+12.10% | 26.61B | |
-22.73% | 18.64B | |
+8.44% | 13.16B | |
+30.32% | 12.55B | |
+24.18% | 12.1B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia